ClinicalTrials.gg
RecruitingNCT06971718Updated May 14, 2025

Coronary Bifurcations With Ischaemia and Flow Assessment

An observational study in Coronary Bifurcation Lesions, sponsored by University of East Anglia. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-14.

Sponsored by University of East Anglia · Observational

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
24
Ages
18 Years and older
Sex
All
01

Study summary

The coronary arteries are blood vessels that provide oxygen rich blood to the muscle of the heart. If these vessels become narrowed or blocked, this can lead to chest pain (called angina) or heart attacks. Narrowings are usually treated using metal scaffolds called drug eluting stents. However, in one in five cases where the narrowing occurs at a branching point, treating it with stents is more challenging and can cause complications. A possible alternative treatment is using a special type of balloon called a drug-coated balloon. This balloon is inflated in the blood vessel and releases medicine to help widen the blood vessel and the procedure is completed without leaving any metallic scaffold behind.

This study aims to compare drug coated balloons with drug eluting stents to see which treatment works better for narrowing that occurs at branching points. We will used advanced imaging techniques to create computer models of blood flow in the vessels, and we will follow up with patients over tie to see how well the treatments work.

02

Conditions studied

  • Coronary Bifurcation Lesions

Keywords

  • Drug coated balloons
  • Coronary bifurcation lesions
  • Computational flow dynamics
03

In context

Lead sponsor

University of East Anglia is the lead sponsor of 79 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Any patient with coronary bifurcation lesion who fulfills the inclusion criteria and is not precluded by the exclusion criteria is suitable for recruitment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or over
  • Any bifurcation lesion amenable to a provisional main vessel treatment strategy
  • A main vessel diameter of 2.5mm or more and side branch diameter of >2mm
  • Any patient with stable angina, silent ischaemia, unstable angina or NSTEMI
  • Able to give

Exclusion criteria

Exclusion Criteria:

  • Cardiogenic shock
  • \<30%
  • STEMI (as unable to give )
  • \<30
  • Severe asthma contraindicating use of adenosine
  • High degree AV block on 12 lead precluding the use of adenosine
  • Pregnancy
  • Inability to consent
  • Left main stem coronary bifurcation lesions
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
24 participants (estimated)
Patient registry
No

Groups and cohorts

  • Drug eluted stent

    Diagnostic Test: Optical coherence tomography and pressure wire assessment of the vessel treated before and after treatment

  • Drug coated balloon

    Diagnostic Test: Optical coherence tomography and pressure wire assessment of the vessel treated before and after treatment

Interventions

  • Diagnostic testOptical coherence tomography and pressure wire assessment of the vessel treated before and after treatment

    OCT and pressure wire of the main vessel and side branch of the bifurcation are undertaken prior to and after treating the lesion and at 3-9 month follow up.

    Also known as: Optical coherence tomography

06

What researchers measure

Primary outcomes

  1. Physiological assessment

    Physiological assessment measuring: * FFR (Main vessel and side branch) * Wall sheer stress

    Time frame: 3-9 months

  2. OCT derived anatomical measure

    Mean lumen area main vessel and mean lumen area side branch

    Time frame: 3-9 months

Secondary outcomes

  1. Late lumen loss

    Angiographic assessment of late lumen loss in main vessel and side branch

    Time frame: 3-9 months

  2. Device oriented clinical endpoints

    Composite of: * Cardiovascular death * Device failure related MI * Device failure related ischaemia * Target bifurcation revascularisation

    Time frame: 3-9 months

  3. Patient focused endpoint: Angina

    Seattle angina questionnaire

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Norwich Medical School, University of East Anglia
    Norwich, Norfolk NR47TJ, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06971718
Lead sponsor
University of East Anglia
Collaborators
Norfolk and Norwich University Hospitals NHS Foundation Trust
Responsible party
Sponsor
First posted
May 14, 2025
Start date
Oct 10, 2023
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
May 14, 2025

Study contacts

Natasha Corballis, MBBS, MRCP (UK), MSc
Contact
natasha.corballis@nnuh.nhs.uk
01603286286
Vassilios S Vassiliou
principal investigator · Norwich Medical School
Simon C Eccleshall
principal investigator · Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion